European Pharma Market

Outlook to 2022 EU-5 Forecast Sales 2022 (€bn)

Size of the market in EU-5 set to grow by

€28.6bn €42.7bn
25% between 2017-2022 with a CAGR of
4.5% over this period
EU-5 accounts for 69% of European
pharma market in 2022 €17.1bn €34.5bn €28.8bn

Germany is forecast to have highest

increase in market value at €9.7bn

Marketed vs. R&D: Historical and Forecast sales to 2022 (€m)

220,000
200,000 By 2022, products
180,000 currently in R&D will
160,000
140,000 account for 13% of
Sales (€m)

120,000 sales in Europe

100,000
80,000
60,000
40,000
20,000 Marketed R&D
0
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

Marketed Products R&D Focus

Xarelto is set to be the biggest selling drug in Europe in 2022 Sanofi’s R&D product Dupixent is forecast to have the
Around 34% of the anti-coagulant product’s sales set to highest sales in 2022
come from Germany Dupixent, currently in Phase III, is set to launch in 2017

Top selling marketed products in 2022 Top selling R&D products in 2022
Product €m Product €m
1. Xarelto €2,820 1. Dupixent €955
2. Eliquis €2,249 2. Bictegravir/F/TAF €776
3. Revlimid €2,195 3. Ocrevus €691
4. Imbruvica €1,830 4. Imfinzi €504
5. Humira €1,674 5. Cevira €499

Key marketed product forecasts to 2022 Key R&D product forecasts to 2022
4,000 1,200
3,500
1,000
3,000 Dupixent
Humira 800
2,500
Sales (€m)

Sales (€m)

Xarelto Ocrevus
2,000 600
Bictegravir
1,500 /F/TAF
Revlimid 400
1,000 Imfinzi
Eliquis 200
500
Imbruvica Cevira
0 0
2016 2017 2018 2019 2020 2021 2022 2016 2017 2018 2019 2020 2021 2022

Source: Evaluate European Drug Forecasts, September 2017. Evaluate European Drug Forecasts are © Copyright 2017 Evaluate Ltd. All rights reserved.
based on consensus forecast estimates combined with government and company reported data.
Evaluate is the trusted provider of commercial intelligence including
product sales and consensus forecasts to 2022 for commercial teams and
their advisors within the global life science industry. We help our clients
make high value decisions through superior quality, timely, must-have
data and insights, combined with personalised, expert client support.

EvaluatePharma® delivers exclusive consensus sales forecasts and

trusted commercial insight into biotech and pharmaceutical performance.
@EvaluatePharma

EvaluateMedTech® sets a new standard in commercial analysis and

consensus forecasts of the global medical device and diagnostic industry.
@EvaluateMedTech

EvaluateClinical Trials® delivers unique clinical trial intelligence expertly

curated to efficiently analyse the global clinical trial landscape.
@EPClinicalTrial

EP Vantage an award winning editorial team, provides daily commentary

and analysis with fresh perspectives and insight into current and future
industry trends.
@EPVantage

Evaluate Custom Services provides customised solutions to help

you access, analyse and manage the information you need to support
effective decision-making.

The Evaluate services enable the life science community to make sound
business decisions about value and opportunity.

Download our Request a

Brochure demo today

www.evaluate.com

Evaluate Headquarters Evaluate Americas Evaluate APAC

Evaluate Ltd. EvaluatePharma USA Inc. Evaluate Japan KK
11-29 Fashion Street 15 Broad Street, Suite 401 Akasaka Garden City 4F
London E1 6PX Boston, MA 02109 4-15-1 Akasaka, Minato-ku
United Kingdom USA Tokyo 107-0052
T +44 (0)20 7377 0800 T +1 617 573 9450 Japan
F +44 (0)20 7539 1801 F +1 617 573 9542 T +81 (0)80 1 164 4754 EDF INFOGRAPHIC – OCT 2017